Opinion|Videos|April 29, 2024
Rentschler Biopharma: A 50-year Legacy of Exceptional CDMO Expertise
Author(s)Rentschler Biopharma
Explore how Rentschler Biopharma duels biopharmaceutical innovation, spanning from pioneering biological products to cutting-edge cell and gene therapies
Benedikt von Braunmühl (CEO) and Federico Pollano (vice president of business development) at Rentschler Biopharma explain what sets their CDMO apart. Viewers will learn about:
- What exceptional CDMO expertise means: 25% of all FDA approved biopharmaceuticals in 2023 were supported by the company
- Rentschler Biopharma’s US offerings, as well as commercial and development expertise
- How the company is leveraging its expertise in the field of gene therapy
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
Trending on Pharmaceutical Technology
1
CNPV Deep Dive: Perspectives on Accelerated FDA Review From the C-Suite to the Manufacturing Floor
2
Is Pharma Solving the Right Problem with its Data Transformation Efforts?
3
Multi-Compendial Compliance for Pharmaceutical Excipients–Part 1: A Practical Application of Specification Equivalence
4
How Codexis is Transforming RNA Manufacturing
5